One of the mechanisms leading to EGFR dysregulation in cancer is the occurrence of activating mutations in the TKD (2), hence we performed sequence analysis of a region of 1329 bp encompassing this domain (~34% of EGFR transcript) as the preliminary step of our experimental plan. Here, EGFR is linked to cancer.